Reidel, V., Kauschinger, J., Hauch, R. T., Müller-Thomas, C., Nadarajah, N., Burgkart, R., . . . Jost, P. J. (2018). Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. Oncotarget.
Citação norma ChicagoReidel, Veronika, et al. "Selective Inhibition of BCL-2 Is a Promising Target in Patients With High-risk Myelodysplastic Syndromes and Adverse Mutational Profile." Oncotarget 2018.
MLA CitationReidel, Veronika, et al. "Selective Inhibition of BCL-2 Is a Promising Target in Patients With High-risk Myelodysplastic Syndromes and Adverse Mutational Profile." Oncotarget 2018.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.